1 active not recruiting, 1 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow PT2385: new trials by email Literature Review of PT2385 trials Research Report on PT2385
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers PT2385 - Healthy | Phase 1 | Completed | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 16 | 2015-09-01 | 2015-12-10 |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) MK-3795, Nivolumab, Cabozantinib - ccRCC, RCC | Phase 1 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 110 | 2014-11-25 | 2024-06-17 |
Carcinoma, Renal Cell (1) · Kidney Neoplasms (1)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2)
United States (2)